A Rsv@HMnO2-HA nanozyme for AKI therapy via targeting inflammatory storm and activating SIRT1/PGC-1α to restore mitochondrial homeostasis - PubMed
3 hours ago
- #Nanomedicine
- #Acute kidney injury
- #Mitochondrial homeostasis
- Development of Rsv@HMnO2-HA nanozyme for AKI therapy targeting inflammation and mitochondrial dysfunction.
- The nanozyme combines resveratrol (Rsv) and ROS-scavenging HMnO2, coated with hyaluronic acid (HA) for kidney targeting.
- HMRH NPs effectively scavenge ROS, attenuate inflammation, and activate SIRT1/PGC-1α to restore mitochondrial homeostasis.
- Mn2+ ions released from the nanozyme enable real-time MRI monitoring of kidney targeting and therapy progress.
- The study demonstrates a synergistic, image-guided nanomedicine approach for AKI treatment and monitoring.